On August 22, 2018 Jiangsu Hengrui Medicine reported that the China National Drug Administration (CNDA) granted a conditional approval to its self-developed compound pyrotinib for treating HER2-positive breast cancer (Press release, Hengrui Pharmaceuticals, AUG 22, 2018, View Source [SID1234591433]). The approval was based on clinical data from phase II studies, demonstrating China’s effort in marketing domestic innovative drugs faster.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!